Lorenzo Pilla
Monza, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.
Journal: Journal for immunotherapy of cancer
Published: October 11, 2020
Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.
Journal: Cancers
Published: September 28, 2020
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Journal: Cells
Published: February 01, 2020
Methods for improving the immunogenicity and efficacy of cancer vaccines.
Journal: Expert opinion on biological therapy
Published: June 08, 2018
Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.
Journal: Biomedicines
Published: May 28, 2018
Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Journal: Breast (Edinburgh, Scotland)
Published: May 25, 2018
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
Journal: Oncoimmunology
Published: June 01, 2015
"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.
Journal: Cancer immunology, immunotherapy : CII
Published: January 21, 2015
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 25, 2014
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Journal: Cancer immunology, immunotherapy : CII
Published: October 09, 2012
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 04, 2012
Last Updated: 09/26/2026